Cardiac function and quality of life improvement with fasudil hydrochloride in patients with diabetes post-PCI: a randomized controlled trial

Fasudil hydrochloride effectively targets endothelial dysfunction and atherosclerosis, contributing to better cardiac performance and metabolic regulation. These effects translate into improved post-PCI quality of life for patients with diabetes and CHD. As an adjunct to standard PCI therapy, fasudil hydrochloride treatment offers a promising strategy for enhancing clinical outcomes in this high-risk patient population.